KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) EPS (Weighted Average and Diluted) (2021 - 2025)

TherapeuticsMD's EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$0.06 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 400.0% year-over-year to -$0.06; the TTM value through Dec 2025 reached -$0.07, up 61.11%, while the annual FY2025 figure was -$0.06, 68.42% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.06 in Q4 2025 per TXMD's latest filing, down from $0.01 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $17.3 in Q4 2022 to a low of -$5.7 in Q1 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.83, with a median of -$0.06 recorded in 2024.
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 337.15% in 2022, then crashed 400.0% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $6.72 in 2021, then surged by 157.44% to $17.3 in 2022, then crashed by 102.25% to -$0.39 in 2023, then surged by 105.13% to $0.02 in 2024, then plummeted by 400.0% to -$0.06 in 2025.
  • Per Business Quant, the three most recent readings for TXMD's EPS (Weighted Average and Diluted) are -$0.06 (Q4 2025), $0.01 (Q3 2025), and $0.05 (Q2 2025).